Clemens Höbaus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7039048/publications.pdf

Version: 2024-02-01

1163117 888059 25 296 8 17 citations g-index h-index papers 25 25 25 569 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	YKL-40 is Elevated in Morbidly Obese Patients and Declines After Weight Loss. Obesity Surgery, 2009, 19, 1557-1563.	2.1	69
2	Endothelial Progenitor Cells Are Related to Glycemic Control in Children With Type 1 Diabetes Over Time. Diabetes Care, 2013, 36, 1647-1653.	8.6	49
3	YKL-40 is elevated in patients with peripheral arterial disease and diabetes or pre-diabetes. Atherosclerosis, 2012, 222, 557-563.	0.8	38
4	Center-based patient care enhances survival of elderly patients suffering from peripheral arterial disease. Annals of Medicine, 2017, 49, 291-298.	3.8	26
5	FABP4 and Cardiovascular Events in Peripheral Arterial Disease. Angiology, 2018, 69, 424-430.	1.8	22
6	Preclinical atherosclerosis and cardiovascular events: Do we have a consensus about the role of preclinical atherosclerosis in the prediction of cardiovascular events?. Atherosclerosis, 2022, 348, 25-35.	0.8	18
7	Predictive power of novel and established obesity indices for outcome in PAD during a five-year follow-up. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1179-1187.	2.6	13
8	Thrombospondin-4 increases with the severity of peripheral arterial disease and is associated with diabetes. Heart and Vessels, 2020, 35, 52-58.	1.2	10
9	YKL-40 levels increase with declining ankle-brachial index and are associated with long-term cardiovascular mortality in peripheral arterial disease patients. Atherosclerosis, 2018, 274, 152-156.	0.8	8
10	Angiopoietin-2 and Survival in Peripheral Artery Disease Patients. Thrombosis and Haemostasis, 2018, 47, 791-797.	3.4	7
11	YKL-40 and its complex association with metabolic syndrome, obesity, and cardiovascular disease. Anatolian Journal of Cardiology, 2016, 16, 959.	0.9	7
12	GlycA for long-term outcome in T2DM secondary prevention. Diabetes Research and Clinical Practice, 2021, 171, 108583.	2.8	6
13	Evaluation of sCD163 and sTWEAK in patients with stable peripheral arterial disease and association with disease severity as well as long-term mortality. Atherosclerosis, 2021, 317, 41-46.	0.8	4
14	Calcification Propensity in Serum and Cardiovascular Outcome in Peripheral Artery Disease. Thrombosis and Haemostasis, 2022, 122, 1040-1046.	3.4	4
15	Gender, metabolic control and carotid intima-media-thickness in children and adolescents with type 1 diabetes mellitus. Wiener Klinische Wochenschrift, 2015, 127, 116-123.	1.9	3
16	Peripheral arterial disease and type 2 diabetes: Older patients still exhibit a survival benefit from glucose control. Diabetes and Vascular Disease Research, 2020, 17, 147916412091484.	2.0	3
17	Peripheral arterial disease and loss of physical function: Just two old friends?. Atherosclerosis, 2017, 257, 246-247.	0.8	2
18	Vascular peroxidase 1 is independently associated with worse kidney function in patients with peripheral artery disease. Journal of Nephrology, 2021, 34, 165-172.	2.0	2

#	Article	IF	CITATIONS
19	Angiogeninâ€"A Proposed Biomarker for Cardiovascular Diseaseâ€"Is Not Associated With Long-Term Survival in Patients With Peripheral Artery Disease. Angiology, 2021, 72, 855-860.	1.8	2
20	Do we need a new classification system for arteriosclerotic lesions in crural limb ischemia? Pros and Cons. Atherosclerosis, 2016, 251, 493-494.	0.8	1
21	Galectin-3 is linked to peripheral artery disease severity, and urinary excretion is associated with long-term mortality. Atherosclerosis, 2022, 341, 7-12.	0.8	1
22	High-Density Lipoprotein Particle Subclasses in Statin-Treated Patients with Peripheral Artery Disease Predict Long-Term Survival. Thrombosis and Haemostasis, 2022, 122, 1804-1813.	3.4	1
23	Chronic kidney disease, mineral bone disease and future risk of peripheral artery disease: Do associations rule?. Atherosclerosis, 2017, 267, 153-155.	0.8	O
24	The enigma to best screen, evaluate and diagnose peripheral artery disease. Atherosclerosis, 2020, 315, 79-80.	0.8	0
25	Soluble urokinase-type plasminogen activator receptor predicts peripheral artery disease severity and outcomes. Vascular Medicine, 2021, 26, 11-17.	1.5	0